Top

Published in:

01-03-2010

High Expression of Claudin-1 Protein in Papillary Thyroid Tumor and its Regional Lymph Node Metastasis

Authors: Júlia Németh, Zsuzsanna Németh, Péter Tátrai, Ilona Péter, Áron Somorácz, Attila Marcell Szász, András Kiss, Zsuzsa Schaff

Published in: Pathology & Oncology Research | Issue 1/2010

Abstract

Claudins, known as major contributors in the formation of the tight junction, are differentially expressed in malignant tumors as compared to the corresponding healthy tissues. Therefore, they are thought to play a role in carcinogenesis and tumor progression. Altered expression of claudin-1 has been reported in several tumor types including endometrial, papillary renal cell and colonic carcinoma, and increased claudin-1 mRNA levels have been observed in papillary thyroid carcinoma (PTC). In this study, we aimed at determining the pattern of claudin-1 expression in various types of thyroid lesions at the protein level and investigating the immunolocalization of β-catenin reported to regulate claudin-1 expression. Samples included 19 PTCs, ten cases of corresponding regional lymph node metastasis, eight papillary microcarcinomas (PMC), 17 follicular thyroid carcinomas (FTC) and 19 follicular adenomas (FA). All cases were evaluated by quantitative immunohistochemistry. Conspicuous claudin-1 immunostaining was detected in the majority of PTC/PMC primary tumors and lymph node metastases (19/27 and 9/10, respectively). On the other hand, we found weak or no claudin-1 expression in any of the FA and FTC cases or peritumoral non-malignant thyroid tissues. Our data prove that high claudin-1 protein expression is specific for PTC and its regional lymph node metastases, while we failed to verify that claudin-1 is regulated by β-catenin in thyroid tumors. Based on these results, claudin-1 may be a useful tumor marker for PTC.

Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803CrossRefPubMed

McNicol A (2007) Pathology of thyroid tumours. Surgery 25:458–462

Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306CrossRefPubMed

DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Thyroid and parathyroid tumours. IARC, Lyon, pp 51–123

Patricia SM (2008) Thyroid epithelial tumours. Diagn Histopathol 14:236–246CrossRef

Arif S, Blanes A, Diaz-Cano SJ (2002) Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathol 41:357–362CrossRef

Di Pasquale M, Rothstein JL, Palazzo JP (2001) Pathologic features of Hashimoto’s-associated papillary thyroid carcinomas. Hum Pathol 32:24–30CrossRefPubMed

Repplinger D, Bargren A, Zhang YW et al (2008) Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150:49–52CrossRefPubMed

González-Mariscal L, Betanzos A, Nava P et al (2003) Tight junction proteins. Prog Biophys Mol Biol 81:1–44CrossRefPubMed

10.

Chiba H, Osanai M, Murata M et al (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778:588–600CrossRefPubMed

11.

Furuse M, Fujita K, Hiiragi T et al (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539–1550CrossRefPubMed

12.

Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186CrossRefPubMed

13.

Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathol 46:551–560CrossRef

14.

Swisshelm K, Macek R, Kubbies M (2005) Role of claudins in tumorigenesis. Adv Drug Deliv Rev 57:919–928 ReviewCrossRefPubMed

15.

Sobel G, Németh J, Kiss A et al (2006) Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 103:591–598CrossRefPubMed

16.

Fritzsche FR, Oelrich B, Johannsen M et al (2008) Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14:7035–7042CrossRefPubMed

17.

Resnick MB, Konkin T, Routhier J et al (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518CrossRefPubMed

18.

Borka K, Kaliszky P, Szabó E et al (2007) Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas. Virchows Arch 450:549–557CrossRefPubMed

19.

Tőkés AM, Kulka J, Paku S et al (2005) Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 7:R296–R305CrossRefPubMed

20.

Sobel G, Páska C, Szabó I et al (2005) Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Hum Pathol 36:162–169CrossRefPubMed

21.

Krause G, Winkler L, Mueller SL et al (2008) Structure and function of claudins. Biochim Biophys Acta 1778:631–645PubMed

22.

Kominsky SL (2006) Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8:1–11CrossRefPubMed

23.

Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65:9603–9606CrossRefPubMed

24.

Tzelepi VN, Tsamandas AC, Vlotinou HD et al (2008) Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 21:22–30CrossRefPubMed

25.

Hucz J, Kowalska M, Jarząb M et al (2006) Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer. Endokrynol Pol 57(SupplA):18–25PubMed

26.

Fluge Ø, Bruland O, Akslen LA et al (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16:161–175CrossRefPubMed

27.

Miwa N, Furuse M, Tsukita S et al (2001) Involvement of claudin-1 in the β-catenin/Tcf signaling pathway and its frequent pregulation in human colorectal cancers. Oncol Res 12:469–476PubMed

28.

Halász J, Holczbauer Á, Cs P, Kovács M, Benyó G, Verebély T, Zs S, Kiss A (2006) Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Human Pathol 37:555–561CrossRef

29.

Liu YY, Morreau H, Kievit J et al (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158:375–384CrossRefPubMed

30.

Dhawan P, Singh AB, Deane NG et al (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115:1765–1776CrossRefPubMed

31.

Wu YL, Zhang S, Wang GR et al (2008) Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol 14:4943–4948CrossRefPubMed

32.

Kondo J, Sato F, Kusumi T et al (2008) Claudin-1 expression is induced by tumor necrosis factor-alpha in human pancreatic cancer cells. Int J Mol Med 22:645–649PubMed

33.

Chao YC, Pan SH, Yang SC et al (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179:123–33CrossRefPubMed

34.

Aldred MA, Huang Y, Liyanarachchi S et al (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22:3531–3539CrossRefPubMed

35.

Firestein R, Bass AJ, Kim SY et al (2008) CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547–551CrossRefPubMed

36.

Elzagheid A, Buhmeida A, Korkeila E et al (2008) Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol 14:3866–3871CrossRefPubMed

37.

Ishigaki K, Namba H, Nakashima M et al (2002) Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433–40CrossRefPubMed

38.

Wang Z, Qiu S, Eltorky MA et al (2007) Histopathologic and immunohistochemical characterization of a primary papillary thyroid carcinoma in the lateral cervical lymph node. Exp Mol Pathol 82:91–4CrossRefPubMed

39.

Nikiforov YE (2008) Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2):S37–43CrossRefPubMed

Title: High Expression of Claudin-1 Protein in Papillary Thyroid Tumor and its Regional Lymph Node Metastasis
Authors: Júlia Németh
Zsuzsanna Németh
Péter Tátrai
Ilona Péter
Áron Somorácz
Attila Marcell Szász
András Kiss
Zsuzsa Schaff
Publication date: 01-03-2010
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-009-9182-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Chromosomal Integration of the HHV-6 Genome as a Possible Cause of Persistent HHV-6 Detection in a Patient with Langerhans Cell Histiocytosis

The Possible Role of Isolated Lymphoid Follicles in Colonic Mucosal Repair

Nasal-type NK/T-cell Lymphoma with Palatal Ulcer as the Earliest Clinical Manifestation: A Case Report with Literature Review

Ependymoma in Adults: Surgery, Reoperation and Radiotherapy for Survival

Changes of AXIN-1 and Beta-Catenin in Neuroepithelial Brain Tumors

Expression and Methylation Pattern of p16 in Neuroblastoma Tumorigenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer